US-UK-artered healthcare AI company Huma Therapeutics has announced the completion of its Series D round with $80 million. With this round, the total funding raised by the company accounts for $300 million.
The round saw participation from new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer and others. HSBC Bank plc acted as advisor to Huma during the fundraise.
Besides this, the company has launched Huma Cloud Platform, the first-of-its-kind GenAI-powered ‘Shopify-like’ experience for the digital health ecosystem to design, build, and launch innovations in quickly.
Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.”
What does the company do?
Founded by Dan Vahdat, Huma works with the a mission to accelerate the adoption of digital solutions in care and research. Its technology powers multi-channel patient engagement at population-wide scale for healthcare systems, remote patient monitoring (RPM) at scale, companion apps to support patients through treatment and drug therapies, and digital clinical trials, including decentralised trials, to accelerate medical research.
Its platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research.
The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies.
Huma Cloud Platform: More details
The platform is built on a robust global regulatory foundation (FDA, EU MDR approved). It aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days.
Huma is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions.
Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work. For example, a feature called “10x Nurse” significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop. This opens new possibilities, such as efficiently managing chronic diseases with fewer staff or using real-time monitoring systems to ensure patients are on the correct treatment pathways while keeping humans still in the loop.
It promises to do this much faster and cheaper, shifting the focus to project or venture success rather than getting distracted with scaling technology or managing regulatory burdens.
In 2023, Huma achieved the milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EuMDR Class IIb, and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. This regulatory status significantly reduces the cost, time, and risks associated with bringing digital health projects to life through the Huma Cloud Platform.
Dan Vahdat, Founder and CEO of Huma, said, “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. They remain consistent and will help us transition medicine from being reactive to proactive.”
What do we think about the company?
Huma Therapeutics, with $80 million in Series D funding, is poised for substantial growth. Its Huma Cloud Platform, leveraging GenAI, accelerates digital health innovation, promising rapid, scalable solutions for healthcare systems and research.
Collaborations with major pharma companies and regulatory approvals enhance its credibility. With a robust global presence and partnerships with tech giants like Google, Huma is set to revolutionise patient care and medical research, transitioning medicine from reactive to proactive, and ensuring affordability and consistency in digital health solutions.
